Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment

2014 ◽  
Vol 21 (S4) ◽  
pp. 610-618 ◽  
Author(s):  
Ping-Li Sun ◽  
Ji Eun Kim ◽  
Seol Bong Yoo ◽  
Hyojin Kim ◽  
Yan Jin ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Lung Adenocarcinomas ◽  
Inhibitor Treatment

scholarly journals Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15418-15434 ◽  
Author(s):  
Carina Heydt ◽  
Sebastian Michels ◽  
Kenneth S. Thress ◽  
Sven Bergner ◽  
Jürgen Wolf ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Novel Approaches ◽  
Inhibitor Resistance

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Sign in / Sign up

Export Citation Format

Share Document